retinoblastoma(redirected from retinoblastomas)
Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to retinoblastomas: Retinal cancer, exophytic retinoblastoma
Retinoblastoma is a malignant tumor of the retina that occurs predominantly in young children.
The eye has three layers, the sclera, the choroid, and the retina. The sclera is the outer protective white coating of the eye. The choroid is the middle layer and contains blood vessels that nourish the eye. The front portion of the choroid is colored and is called the iris. The opening in the iris is called the pupil. The pupil is responsible for allowing light into the eye and usually appears black. When the pupil is exposed to bright light it contracts (closes), and when it is exposed to low light conditions it dilates (opens) so that the appropriate amount of light enters the eye. Light that enters through the pupil hits the lens of the eye. The lens then focuses the light onto the retina, the innermost of the three layers. The job of the retina is to transform the light into information that can be transmitted to the optic nerve, which will transmit this information to the brain. It is through this process that people are able to see the world around them.
Occasionally a tumor, called a retinoblastoma, will develop in the retina of the eye. Usually this tumor forms in young children but it can occasionally occur in adults. Most people with retinoblastoma develop only one tumor (unifocal) in only one eye (unilateral). Some, however, develop multiple tumors (multifocal) in one or both eyes. When retinoblastoma occurs independently in both eyes, it is then called bilateral retinoblastoma.
Occasionally, children with retinoblastoma develop trilateral retinoblastoma. Trilateral retinoblastoma results from the development of an independent brain tumor that often forms in a part of the brain called the pineal gland. In order for retinoblastoma to be classified as trilateral retinoblastoma, the tumor must have developed independently and not as the result of the spread of the retinal cancer. The prognosis for trilateral retinoblastoma is quite poor.
The retinal tumor which characterizes retinoblastoma is malignant, meaning that it can metastasize (spread) to other parts of the eye and eventually other parts of the body. In most cases, however, retinoblastoma is diagnosed before it spreads past the eye to other parts of the body (intraocular) and the prognosis is quite good. The prognosis is poorer if the cancer has spread beyond the eye (extraocular).
Retinoblastoma can be inherited or can arise spontaneously. Approximately 40% of people with retinoblastoma have an inherited form of the condition and approximately 60% have a sporadic (not inherited) form. Individuals with multiple independent tumors, bilateral retinoblastoma, or trilateral retinoblastoma are more likely to be affected with the inherited form of retinoblastoma.
Approximately 1 in 15,000 to 1 in 30,000 infants in Western countries are born with retinoblastoma, making it the most common childhood eye cancer. It is, however, a relatively rare childhood cancer and accounts for approximately 3% of childhood cancers. The American Academy of Ophthalmology estimates that 300-350 cases of retinoblastoma occur in the United States each year.
Retinoblastoma is found mainly in children under the age of five but can occasionally be seen in older children and adults. Retinoblastoma is found in individuals of all ethnic backgrounds and is found equally frequently in males and females. The incidence of bilaterial retinoblastoma in the United States is thought to be slightly higher among black children than among either Caucasian or Asian American children.
Causes and symptoms
Retinoblastoma is caused by changes in or absence of a gene called RB1. RB1 is located on the long arm of chromosome 13. Cells of the body, with the exception of the egg and sperm cells, contain 23 pairs of chromosomes. All of the cells of the body excluding the egg and the sperm cells are called the somatic cells. The somatic cells contain two of each chromosome 13 and therefore two copies of the RB1 gene. Each egg and sperm cell contains only one copy of chromosome and therefore only one copy of the RB1 gene.
RB1 produces a tumor suppressor protein that normally helps to regulate the cell cycle of cells such as those of the retina. A normal cell of the retina goes through a growth cycle during which it produces new cells. Genes such as tumor suppressor genes tightly regulate this growth cycle.
Cells that lose control of their cell cycle and replicate out of control are called cancer cells. These undergo many cell divisions, often at a quicker rate than normal cells, and do not have a limited lifespan. A group of adjacent cancer cells can form a mass called a tumor. Malignant (cancerous) tumors can spread to other parts of the body. A malignant tumor of the retina (retinoblastoma) can result when just one retinal cell looses control of it cell cycle and replicates out of control.
Normally the tumor suppressor protein produced by RB1 prevents a retinal cell from becoming cancerous. Each RB1 gene produces tumor suppressor protein. Only one functioning RB1 gene in a retinal cell is necessary to prevent the cell from becoming cancerous. If both RB1 genes in a retinal cell become non-functional, then a retinal cell can become cancerous and retinoblastoma can result. An RB1 gene is non-functional when it is changed or missing (deleted) and no longer produces normal tumor suppressor protein.
Approximately 40% of people with retinoblastoma have inherited a non-functional or deleted RB1 gene from either their mother or father. Therefore, they have a changed/deleted RB1 gene in every somatic cell. A person with an inherited missing or non-functional RB1 gene will develop a retinal tumor if the remaining RB1 gene becomes changed or deleted in a retinal cell. The remaining RB1 gene can become non-functional when exposed to environmental triggers such as chemicals and radiation. In most cases, however, the triggers are unknown. Approximately 90% of people who inherit a changed or missing RB1 gene will develop retinoblastoma.
People with an inherited form of retinoblastoma are more likely to have a tumor in both eyes (bilateral) and are more likely to have more than one independent tumor (multifocal) in one or both eyes. The average age of onset for the inherited form of retinoblastoma is one year, which is earlier than the sporadic form of retinoblastoma. Although most people with the inherited form of retinoblastoma develop bilateral tumors, approximately 15% of people with a tumor in only one eye (unilateral) are affected with an inherited form of retinoblastoma.
A person with an inherited missing or nonfunctional RB1 gene has a 50% chance of passing on this abnormal gene to his or her offspring. The chance that their children will inherit the changed/deleted gene and actually develop retinoblastoma is approximately 45%.
Some people with retinoblastoma have inherited a non-functioning or missing RB1 gene from either their mother or father even though their parents have never developed retinoblastoma. It is possible that one parent has a changed or missing RB1 gene in every somatic cell but has not developed retinoblastoma because their remaining RB1 gene has remained functional. It is also possible that the parent had developed a retinal tumor that was destroyed by the body. In other cases, one parent has two normal RB1 genes in every somatic cell, but some of their egg or sperm cells contain a changed or missing RB1 gene. This is called gonadal mosaicism.
Retinoblastoma can also result when both RB1 genes become spontaneously changed or deleted in a retinal cell but the RB1 genes are normal in all the other cells of the body. Approximately 60% of people with retinoblastoma have this type of disease, called sporadic retinoblastoma. A person with sporadic retinoblastoma does not have a higher chance of having children with the disease. Their relatives do not have a higher risk of developing retinoblastoma themselves or having children who develop retinoblastoma. Sporadic retinoblastoma is usually unifocal and has an average age of onset of approximately two years.
The most common symptom of retinoblastoma is leukocoria. Leukocoria results when the pupil reflects a white color rather than the normal black or red color that is seen on a flash photograph. It is often most obvious in flash photographs; since the pupil is exposed to a lot of light and the duration of the exposure is so short, the pupil does not have time to constrict. Children with retinoblastoma can also have problems seeing and this can cause them to appear cross-eyed (strabismus). People with retinoblastoma may also experience red, painful, and irritated eyes, inflamed tissue around the eye, enlarged pupils, and possibly different-colored eyes.
Children who have symptoms of retinoblastoma are usually first evaluated by their pediatrician. The pediatrician will often perform a red reflex test to diagnose or confirm leukocoria. Prior to this test the doctor inserts medicated eye drops into the child's eyes so that the pupils will remain dilated and not contract when exposed to bright light. The doctor then examines the eyes with an ophthalmoscope, which shines a bright light into the eyes and allows the doctor to check for leukocoria. Leukocoria can also be diagnosed by taking a flash Polaroid photograph of a patient who has been in a dark room for three to five minutes.
If the pediatrician suspects retinoblastoma on the basis of these evaluations, he or she will most likely refer the patient to an ophthalmologist (eye doctor) who has experience with retinoblastoma. The ophthalmologist will examine the eye using an indirect ophthalmoscope. The opthalmoscope shines a bright light into the eye, which helps the doctor to visualize the retina. This evaluation is usually done under general anesthetic, although some very young or older patients may not require it. Prior to the examination, medicated drops are put into the eyes to dilate the pupils, and anesthetic drops may also be used. A metal clip is used to keep the eyes open during the evaluation. During the examination, a cotton swab or a metal instrument with a flattened tip is used to press on the outer lens of the eye so that a better view of the front areas of the retina can be obtained. Sketches or photographs of the tumor as seen through the ophthalmoscope are taken during the procedure.
An ultrasound evaluation is used to confirm the presence of the tumor and to evaluate its size. Computed axial tomography (CT scan) is used to determine whether the tumor has spread outside of the eye and to the brain. Sometimes magnetic resonance imaging (MRI) is also used to look at the eyes, eye sockets, and the brain to see if the cancer has spread.
In most cases the cancer has not spread beyond the eye, and other evaluations are unnecessary. If the cancer appears to have spread beyond the eye, then other assessments such as a blood test, spinal tap (lumbar puncture), and/or bone marrow biopsy may be recommended. During a spinal tap, a needle is inserted between the vertebrae of the spinal column and a small sample of the fluid surrounding the spinal cord is obtained. In a bone marrow biopsy, a small amount of tissue (bone marrow) is taken from inside the hip or breast bone for examination.
Establishing whether someone is affected with an inherited or non-inherited form of retinoblastoma can help to ascertain whether other family members such as siblings, cousins, and offspring are at increased risk for developing retinoblastoma. It can also sometimes help guide treatment choices, since patients with an inherited form of retinoblastoma may be at increased risk for developing recurrent tumors or other types of cancers, particularly when treated with radiation. It is helpful for the families of a child diagnosed with retinoblastoma to meet with a genetic specialist such as a genetic counselor and/or geneticist. These specialists can help to ascertain the chances that the retinoblastoma is inherited and facilitate genetic testing if desired.
If a patient with unilateral or bilateral retinoblastoma has a relative or relatives with retinoblastoma, it can be assumed that they have an inherited form of retinoblastoma. However, it cannot be assumed that a patient without a family history of the disease has a sporadic form.
Even when there is no family history, most cases of bilateral and trilateral retinoblastoma are inherited, as are most cases of unilateral, multifocal retinoblastoma. However, only 15% of unilateral, unifocal retinoblastoma cases are inherited.
The only way to establish whether someone has an inherited form of retinoblastoma is to see if the retinoblastoma gene is changed or deleted in the blood cells obtained from a blood sample. Approximately 5-8% of individuals with retinoblastoma possess a chromosomal abnormality involving the RB1 gene that can be detected by looking at their chromosomes under the microscope. The chromosomes can be seen by obtaining a blood sample. If this type of chromosomal abnormality is detected in a child, then analysis of the parents' chromosomes should be performed. If one of the parents possesses a chromosomal abnormality, then they are at higher risk for having other offspring with retinoblastoma. Chromosome testing would be recommended for the blood relatives of the parent with the abnormality.
Usually, however, a chromosomal abnormality is not detected in a child with retinoblastoma. In this case, specialized DNA tests that look for small RB1 gene changes need to be performed on the blood cells. DNA testing can be difficult, time consuming, and expensive, since there are many possible RB1 gene changes that can cause the gene to become nonfunctional.
If a sample of tumor is available, then it is recommended that DNA testing be performed on the tumor cells prior to DNA testing of the blood cells. This testing can usually identify the gene changes/deletions in the RB1 genes that caused the tumor to develop. In some cases, RB1 gene changes/deletions are not found in the tumor cells (as of 2001, approximately 20% of RB1 gene changes or deletions are not detectable). In these cases, DNA testing of the blood cells will not be able to ascertain whether someone is affected with an inherited or non-inherited form of retinoblastoma.
If the changes in both RB1 genes are detected in the tumor cell, then these same changes can be looked for in the blood cells. If an RB1 gene is deleted or changed in all of the blood cells tested, the patient can be assumed to have been born with a changed/deleted RB1 gene in all of their cells. This person has a 50% chance of passing the RB1 gene change/deletion on to his or her children. Most of the time, this change/deletion has been inherited from a parent. Occasionally the gene change/deletion occurred spontaneously in the original cell that was formed when the egg and sperm came together at conception (de novo).
If an RB1 gene change/deletion is found in all of the blood cells tested, both parents should undergo blood testing to check for the same RB1 gene change/deletion. If the RB1 gene change/deletion is identified in one of the parents, it can be assumed that the retinoblastoma was inherited and that siblings have a 50% chance of inheriting the altered gene. More distant blood relatives of the parent with the identified RB1 gene change/deletion may also be at risk for developing retinoblastoma. Siblings and other relatives could undergo DNA testing to see if they have inherited the RB1 gene change/deletion.
If the RB1 gene change/deletion is not identified in either parent, then the results can be more difficult to interpret. In this case, there is a 90-94% chance that the retinoblastoma was not inherited.
In some cases, a person with retinoblastoma will have an RB1 gene change/deletion detected in some of their blood cells and not others. It can be assumed that this person did not inherit the retinoblastoma from either parent. Siblings and other relatives would therefore not be at increased risk for developing retinoblastoma. Offspring would be at increased risk since some of the egg or sperm cells could have the changed/deleted RB1 gene. The risks to offspring would probably be less than 50%.
In families where there are multiple family members affected with retinoblastoma, blood samples from multiple family members are often analyzed and compared through DNA testing. Ninety-five percent of the time, this type of analysis is able to detect patterns in the DNA that are associated with a changed RB1 gene in that particular family. When a pattern is detected, at-risk relatives can be tested to establish whether they have inherited an RB1 gene change/deletion.
PRENATAL TESTING. If chromosome or DNA testing identifies an RB1 gene/deletion in someone's blood cells, then prenatal testing can be performed on this person's offspring. An amniocentesis or chorionic villus sampling can be used to obtain fetal cells which can be analyzed for the RB1 gene change/deletion or chromosomal abnormality.
A number of different classification (staging) systems are used to establish the severity of retinoblastoma and aid in choosing an appropriate treatment plan. The most widely used staging system is the Reese-Ellsworth system. This system is used to classify intraocular tumors and predict which tumors are favorable enough that sight can be maintained. The Reese-Ellsworth classification system is divided into:
- Group I (very favorable for maintenance of sight): small solitary or multiple tumors, less than 6.4 mm in size (1 inch = 25.4 mm), located at or below the equator of the eye
- Group II (favorable for maintenance of sight): solitary or multiple tumors, 6.4-16 mm in size, located at or behind the equator of the eye
- Group III (possible for maintenance of sight): any tumor located in front of the equator of the eye, or a solitary tumor larger than 16 mm in size and located behind the equator of the eye
- Group IV (unfavorable for maintenance of sight): multiple tumors, some larger than 16 mm in size, or any tumor extending in front of the outer rim of the retina (ora serrata)
- Group V (very unfavorable for maintenance of sight): large tumors involving more than half of the retina, or vitreous seeding, in which small pieces of tumor are broken off and floating around the inside of the eye
When choosing a treatment plan, the first important criteria to ascertain is whether the cancer is localized within the eye (intralocular) or has spread to other parts of the body (extralocular). An intraocular retinoblastoma may only involve the retina or could involve other parts of the eye. An extraocular retinoblastoma could involve only the tissues around the eye or could result from the spread of cancer to the brain or other parts of the body.
It is also important to establish whether the cancer is unilateral (one eye) or bilateral (both eyes), multifocal or unifocal. In order for the tumors to be considered multifocal, they must have arisen independently and not as the result of the spread of cancer cells. It is also important to check for trilateral retinoblastoma.
The treatment chosen depends on the size and number of tumors, whether the cancer is unilateral or bilateral, and whether the cancer has spread to other parts of the body. The goal of treatment is to cure the cancer and prevent as much loss of vision as possible. Since the late 1990s, doctors treating patients with retinoblastoma have tended to avoid enucleation and external beam radiation therapy whenever possible, in favor of chemotherapy to reduce the tumor in addition to focal therapies. Improved methods of chemoreduction have led to increasing success in saving patients' eyes, often with some visual function.
TREATMENT OF INTRAOCULAR TUMORS. Surgical removal of the affected eye (enucleation) is used when the tumor(s) are so large and extensive that preservation of sight is not possible. This surgery is performed under general anesthetic and usually takes less than an hour. Most children who have undergone this surgery can leave the hospital on the same day. A temporary ball is placed in the eye socket after the surgery. Approximately three weeks after the operation, a plastic artificial eye (prosthesis) that looks like the normal eye is inserted into the eye socket.
Radiation therapy is often used for treatment of large tumors when preservation of sight is possible. External beam radiation therapy involves focusing a beam of radiation on the eye. If the tumor has not spread extensively, the radiation beam can be focused on the cancerous retinal cells. If the cancer is extensive, radiation treatment of the entire eye may be necessary. External beam radiation is performed on an outpatient basis and usually occurs over a period of three to four weeks. Some children may need sedatives prior to the treatment. This type of therapy can result in a temporary loss of a patch of hair on the back of the head and a small area of "sun-burned" skin. Long-term side effects of radiation treatment can include cataracts, vision problems, bleeding from the retina, and decreased growth of the bones on the side of the head. People with an inherited form of retinoblastoma have an increased risk of developing other cancers as a result of this therapy. Some consideration should therefore be given to alternative treatment therapies for those with an inherited form of retinoblastoma.
Photocoagulation therapy is often used in conjunction with radiation therapy but may be used alone to treat small tumors that are located on the back of the eye. Photocoagulation involves using a laser to destroy the cancer cells. This type of treatment is done under local or general anesthesia and is usually not associated with post-procedural pain.
Thermotherapy is also often used in conjunction with radiation therapy or drug therapy (chemotherapy). Thermotherapy involves the use of heat to help shrink tumor cells. The heat is either used on the whole eye or localized to the tumor area. It is done under local or general anesthesia and is usually not painful.
Cryotherapy is a treatment often used in conjunction with radiation therapy but can also be used alone on small tumors located on the front part of the retina. Cryotherapy involves the use of intense cold to destroy cancer cells and can result in harmless, temporary swelling of the external eye and eyelids that can last for up to five days. Eye drops or ointment are sometimes provided to reduce the swelling.
Brachytherapy involves the application of radioactive material to the outer surface of the eye at the base of the tumor. It is generally used for tumors of medium size. A patient undergoing this type of procedure is usually hospitalized for three to seven days. During that time, he or she undergoes one surgery to attach the radioactive material and one surgery to remove it. Eye drops are often administered for three to four weeks following the operation to prevent inflammation and infection. The long-term side effects of this treatment can include cataracts and damage to the retina, which can lead to impaired vision.
Intravenous treatment with one or more drugs (chemotherapy) is often used for treatment of both large and small tumors. Chemotherapy is sometimes used to shrink tumors prior to other treatments such as radiation therapy or brachytherapy. Occasionally, it is also used alone to treat very small tumors.
TREATMENT OF INTRAOCULAR AND UNILATERAL RETINOBLASTOMA. Often, by the time that unilateral retinoblastoma is diagnosed, the tumor is so large that useful vision cannot be preserved. In these cases removal of the eye (enucleation) is the treatment of choice. Other therapies are unnecessary if enucleation is used to treat intraocular unilateral retinoblastoma. If the tumor is small enough, other therapies such as external beam radiation therapy, photocoagulation, cryotherapy, thermotherapy, chemotherapy, and brachytherapy may be considered.
TREATMENT OF INTRAOCULAR AND BILATERAL RETINOBLASTOMA. If vision can be preserved in both eyes, radiation therapy of both eyes may be recommended. Smaller, more localized tumors can sometimes be treated by local therapies such as cryotherapy, photocoagulation therapy, thermotherapy or brachytherapy. Some centers may use chemotherapy in place of radiation therapy when the tumors are too large to be treated by local therapies or are found over the optic nerve of the eye. Many centers are moving away from radiation treatment and toward chemotherapy because it is less likely to induce future tumors. Enucleation is performed on the more severely affected eye if sight cannot be preserved in both.
EXTRAOCULAR RETINOBLASTOMA. There is no proven effective therapy for the treatment of extraocular retinoblastomas. Commonly, radiation treatment of the eyes and chemotherapy is provided.
There are no alternative or complementary therapies specific to the treatment of retinoblastoma. Since most people diagnosed with retinoblastoma are small children, most drug-based alternative therapies designed to treat general cancer would not be recommended. Many specialists would, however, stress the importance of establishing a well-balanced diet, including certain fruits, vegetables, and vitamin supplements, to ensure that the body is strengthened in its fight against cancer. Some advocate the use of visualization strategies, in which patients would visualize the immune cells of their body attacking and destroying the cancer cells.
Individuals with intraocular retinoblastoma who do not have trilateral retinoblastoma usually have a good survival rate with a 90% chance of disease-free survival for five years. Those with extraocular retinoblastoma have less than a 10% chance of disease-free survival for the same amount of time. Trilateral retinoblastoma generally has a very poor prognosis. Patients with trilateral retinoblastoma who receive treatment have an average survival rate of approximately eight months, while those who remain untreated have an average survival rate of approximately one month. Patients with trilateral retinoblastoma who are asymptomatic at the time of diagnosis may have a better prognosis then those who experience symptoms.
Patients with an inherited form of unilateral retinoblastoma have a 70% chance of developing retinoblastoma in the other eye. Retinoblastoma reoccurs in the other eye in approximately 5% of people with a non-inherited form of retinoblastoma, so it is advisable for even these patients to be closely monitored. People with an inherited form of retinoblastoma who have not undergone radiation treatment have approximately a 26% chance of developing cancer in another part of the body within 50 years of the initial diagnosis. Those with an inherited form who have undergone radiation treatment have a 58% chance of developing a secondary cancer by 50 years after the initial diagnosis. Most of the secondary cancers are skin cancers, bone tumors (osteosarcomas), and soft-tissue sarcomas. Soft-tissue sarcomas are malignant tumors of the muscle, nerves, joints, blood vessels, deep skin tissues, or fat. The prognosis for retinoblastoma patients who develop secondary cancers, however, is very poor as of the early 2000s.
Survivors of retinoblastoma are likely to have visual field defects after their cancer treatment is completed, most commonly scotomas, which are areas of lost or depressed vision within an area of normal vision. The size and type of these visual defects are determined by the size and type of the original tumor and the form of therapy used to treat it.
Although retinoblastoma cannot be prevented, appropriate screening and surveillance should be applied to all at-risk individuals to ensure that the tumor(s) are diagnosed at an early stage. The earlier the diagnosis, the more likely that an eye can be salvaged and vision maintained.
Screening of people diagnosed with retinoblastoma
Children who have been diagnosed with retinoblastoma should receive periodic dilated retinal examinations until the age of five. Young children will need to undergo these evaluations under anesthetic. After five years of age, periodic eye examinations are recommended. It may be advisable for patients with bilateral retinoblastoma or an inherited form of retinoblastoma to undergo periodic screening for the brain tumors found in trilateral retinoblastoma. There are no specific screening protocols designed to detect non-ocular tumors. All lumps and complaints of bone pain, however, should be thoroughly evaluated.
Screening of relatives
When a child is diagnosed with retinoblastoma, it is recommended that parents and siblings receive a dilated retinal examination by an ophthalmologist who is experienced in the diagnosis and treatment of the disease. It is also recommended that siblings continue to undergo periodic retinal examinations under anesthetic until they are three years of age. From three to seven years of age, periodic eye examinations are recommended. The retinal examinations can be avoided if DNA testing indicates that the patient has a non-inherited form of retinoblastoma or if the sibling has not inherited the RB1 gene change/deletion. Any relatives who are found through DNA testing to have inherited an RB1 gene change/deletion should undergo the same surveillance procedures as siblings.
The children of someone diagnosed with retinoblastoma should also undergo periodic retinal examinations under anesthetic. Retinal surveillance should be performed unless DNA testing proves that their child does not possess the RB1 gene change/deletion. If desired, prenatal detection of tumors using ultrasound may also be performed. During the ultrasound procedure, a hand-held instrument is placed on the maternal abdomen or inserted vaginally. The ultrasound produces sound waves that are reflected back from the body structures of the fetus, producing a picture that can be seen on a video screen. If a tumor is detected through this evaluation, the affected baby may be delivered a couple of weeks earlier. This can allow for earlier intervention and treatment.
Beers, Mark H., MD, and Robert Berkow, MD., editors. "Retinoblastoma." In The Merck Manual of Diagnosis and Therapy. Whitehouse Station, NJ: Merck Research Laboratories, 2004.
Abramson, D. H., M. R. Melson, and C. Servodidio. "Visual Fields in Retinoblastoma Survivors." Archives of Ophthalmology 122 (September 2004): 1324-1330.
Aerts, I., H. Pacquement, F. Doz, et al. "Outcome of Second Malignancies after Retinoblastoma: A Retrospective Analysis of 25 Patients Treated at the Institut Curie." European Journal of Cancer 40 (July 2004): 1522-1529.
Lohmann, D. R., and B. L. Gallie. "Retinoblastoma: Revisiting the Model Prototype of Inherited Cancer." American Journal of Medical Genetics, Part C: Seminars in Medical Genetics 129 (August 15, 2004): 23-28.
Provenzale, J. M., S. Gururangan, and G. Klintworth. "Trilateral Retinoblastoma: Clinical and Radiologic Progression." AJR: American Journal of Roentgenology 183 (August 2004): 505-511.
Shields, C. L., A. Mashayeki, J. Cater, et al. "Chemoreduction for Retinoblastoma. Analysis of Tumor Control and Risks for Recurrence in 457 Tumors." American Journal of Ophthalmology 138 (September 2004): 329-337.
Shields, C. L., and J. A. Shields. "Diagnosis and Management of Retinoblastoma." Cancer Control 11 (September-October 2004): 317-327.
Amniocentesis — Prenatal testing performed at 16 to 20 weeks of pregnancy that involves inserting a needle through the abdomen of a pregnant mother and obtaining a small sample of fluid from the amniotic sack, which contains the fetus. Often is used to obtain a sample of the fetus' cells for biochemical or DNA testing.
Benign tumor — An abnormal proliferation of cells that does not spread to other parts of the body.
Bilateral — Affecting both eyes.
Brachytherapy — Cancer treatment that involves the application of radioactive material to the site of the tumor.
Chorionic villus sampling (CVS) — Prenatal testing performed at 10 to 12 weeks of pregnancy, which involves inserting a catheter through the vagina of a pregnant mother or inserting a needle through the abdomen of the mother and obtaining a sample of placenta. Often is used to obtain a sample of the fetus' cells for biochemical or DNA testing.
Chromosome — A microscopic structure found within each cell of the body, made of a complex of proteins and DNA.
Cryotherapy — Cancer treatment in which the tumor is destroyed by exposure to intense cold.
DNA (deoxyribonucleic acid) — The hereditary material that makes up genes; influences the development and functioning of the body.
DNA testing — Testing for a change or changes in a gene or genes.
Enucleation — Surgical removal of the eye.
Equator — Imaginary line encircling the eyeball and dividing the eye into a front and back half.
Extraocular retinoblastoma — Cancer that has spread from the eye to other parts of the body.
Gene — A building block of inheritance, made up of a compound called DNA (deoxyribonucleic acid) and containing the instructions for the production of a particular protein. Each gene is found in a specific location on a chromosome.
Intraocular retinoblastoma — Cancer that is limited to the eye and has not spread to other parts of the body.
Malignant tumor — An abnormal proliferation of cells that can spread to other sites.
Multifocal — More than one tumor present.
Oncologist — A physician specializing in the diagnosis and treatment of cancer
Ophthalmologist — Physician specializing in the diseases of the eye.
Optic nerve — The part of the eye which contains nerve fibers that transmit signals from the eye to the brain.
Photocoagulation — Cancer treatment in which the tumor is destroyed by an intense beam of laser light.
Prenatal testing — Testing for a disease such as a genetic condition in an unborn baby.
Protein — A substance produced by a gene that is involved in creating the traits of the human body, such as hair and eye color, or is involved in controlling the basic functions of the human body, such as control of the cell cycle.
Retina — The light-sensitive layer of the eye that receives images and sends them to the brain.
Scotoma — An area of lost or depressed vision within the visual field surrounded by an area of normal vision. Survivors of retinoblastoma frequently develop scotomas.
Somatic cells — All the cells of the body with the exception of the egg and sperm cells.
Tumor — A growth of tissue resulting from the uncontrolled proliferation of cells.
Tumor-suppressor gene — Gene involved in controlling normal cell growth and preventing cancer.
Unifocal — Only one tumor present in one eye.
Unilateral — Affecting only one eye.
Vitreous — The transparent gel that fills the back part of the eye.
Vitreous seeding — When small pieces of tumor have broken off and are floating around the vitreous.
American Academy of Ophthalmology (AAO). P. O. Box 7424, San Francisco, CA 94120-7424. (415) 561-8500. Fax: (415) 561-8533. http://www.aao.org.
Institute for Families with Blind Children. PO Box 54700, Mail Stop 111, Los Angeles, CA 90054-0700. (213) 669-4649.
National Retinoblastoma Parents Group. PO Box 317, Watertown, MA 02471. (800) 562-6265. Fax: (617) 972-7444. firstname.lastname@example.org.
Retinoblastoma International. 4650 Sunset Blvd., Mail Stop #88, Los Angeles, CA 90027. (323) 669-2299. email@example.com. 〈http://www.retinoblastoma.net/rbi/index_rbi.htm〉.
Retinoblastoma Society. Saint Bartholomew's Hospital, London, UK EC1A 7BE. Phone: 020 7600 3309 Fax: 020 7600 8579. 〈http://ds.dial.pipex.com/rbinfo〉.
Abramson, David, and Camille Servodidio. "A Parent's Guide to Understanding Retinoblastoma." June 20, 2001. 〈http://www.retinoblastoma.com/guide/guide.html〉.
Kid's Eye Cancer. June 20, 2001. http://www.kidseyecancer.org.
Lohmann, Dietmar, N. Bornfeld, B. Horsthemke, and E. Passarge. "Retinoblastoma." Gene Clinics. July 17, 2000. [cited June 20, 2001]. 〈http://www.geneclinic-s.org/profiles/retinoblastoma〉.
McCusick, Victor. "Retinoblastoma; RB1." Online Mendelian Inheritance in Man. February 14, 2001. [cited June 20, 2001. http://www.ncbi.nlm.nih.gov/Omim.
"Retinoblastoma" CancerNet. 〈http://cancernet.nci.nih.gov/Cancer_Types/Retinoblastoma.shtml〉.
Solutions by Sequence. June 20, 2001. http://www.solutionsbysequence.com.
a malignant congenital hereditary blastoma composed of retinal cells arising from the nuclear layers, appearing in one or both eyes in children under 5 years of age, and usually diagnosed initially by a bright white or yellow pupillary reflex (leukokoria).
ret·i·no·blas·to·ma(ret'i-nō-blas-tō'mă), [MIM*180200, MIM*180201, MIM*180202]
Malignant ocular neoplasm of childhood, with onset usually before the third year of life, composed of primitive retinal small round cells with deeply staining nuclei and elongated cells forming rosettes; the risk of developing osteosarcoma increases later in life. In familial cases, the disease is usually bilateral with multiple lesions within an eye, but in sporadic cases rarely so. Autosomal dominant inheritance caused by mutation in the tumor-suppressor retinoblastoma gene (RB) on chromosome 13q.
[retino- + G. blastos, germ, + -oma, tumor]
retinoblastoma/ret·i·no·blas·to·ma/ (ret″ĭ-no-blas-to´mah) a malignant congenital blastoma, hereditary or sporadic, composed of tumor cells arising from the retinoblasts.
endophytic retinoblastoma , retinoblastoma endo´phytum a retinoblastoma that begins in the inner layers of the retina and spreads toward the center of the globe.
exophytic retinoblastoma , retinoblastoma exo´phytum a retinoblastoma that begins in the outer layers of the retina and spreads away from the center of the globe.
n. pl. retinoblasto·mas or retinoblasto·mata (-mə-tə)
A hereditary malignant tumor of the retina, transmitted as a dominant trait and occurring chiefly among infants.
[ret′inōblastō′mə] pl. retinoblastomas, retinoblastomata
Etymology: L, rete + Gk, blastos, germ, oma, tumor
a congenital hereditary neoplasm developing from retinal germ cells. Characteristic signs are diminished vision, strabismus, retinal detachment, and an abnormal pupillary reflex. The rapidly growing tumor may invade the brain and metastasize to distant sites. Treatment includes removal of the eye and as much of the optic nerve as possible, followed by radiation and chemotherapy. It is bilateral in about 30% of the cases. The more affected eye is enucleated, and the other eye is treated with radiation, antibiotics, cryotherapy, or photocoagulation, singly or in combination. Because many of the cases are transmitted as an autosomal-dominant trait with incomplete penetration, genetic counseling is advisable.
retinoblastomaCancer of retina Oncology A CA, usually of children–affecting 1:15-30 000 infants–that arises in retinal cells, which has photoreceptor differentiation; 10-20% are hereditary, mostly AD; 70% are unilateral and arise de novo; bilateral tumors are associated with germ cell neoplasms and occasionally other tumors–eg, osteogenic sarcoma, Ewing sarcoma Treatment RT. See One-hit, two-hit model, Flexner-Wintersteiner rosettes.
Malignant ocular neoplasm of childhood, usually occurring before the third year of life, composed of primitive retinal small round cells with deeply staining nuclei and of elongate cells forming rosettes. In familial forms, the disease is commonly bilateral and multiple within an eye; in sporadic cases, rarely so.
[retino- + G. blastos, germ, + -oma, tumor]
retinoblastomaA highly malignant tumour of the RETINA affecting babies and young children and usually presenting as a squint (strabismus) or as a visible whiteness in the pupil. In one-third of cases both eyes are affected. Retinoblastoma can spread to all parts of the body and early removal of the affected eye is often advised. If there is tumour in both eyes, radiotherapy is given to the less severely affected eye. Retinoblastoma is a genetic disorder inherited as an autosomal dominant. There is evidence that the genetic basis for retinoblastoma is loss of a tumour-suppressor gene on chromosome 13. Loss of the homologous normal retinoblastoma gene is also necessary for the tumour to develop. Because of the genetic basis it is important for other young children in the family to be examined by an ophthalmologist.
A congenital malignant tumour of the retina usually noted in the first two years of life, although in some cases it may not be until after age five years. It is the most common intraocular tumour of childhood. The condition is inherited in about 40% of all cases. The predisposing gene (RB1) is located on chromosome 13q14. Most individuals who inherit a mutant copy of the retinoblastoma gene sustain a second hit to the remaining normal copy of the gene and develop the disease. The most common ocular manifestations are leukokoria and strabismus and sometimes, red eye, glaucoma and orbital cellulitis. Diagnosis is usually made by the appearance of a greyish reflex of light observed at the pupil, although often by that time the pupil is fixed and the eye is blind. Computerized tomography is useful in imaging the tumour. Treatment includes external beam radiotherapy, photocoagulation, cryotherapy and chemotherapy while advanced tumours are managed by enucleation. Syn. retinal glioma. See chromosome; penetrance; cat's eye reflex.
ret·i·no·blas·to·ma(ret'i-nō-blas-tō'mă) [MIM*180200, 180201, 180202]
Malignant ocular neoplasm of childhood.
[retino- + G. blastos, germ, + -oma, tumor]
n a congenital, hereditary neoplasm developing from retinal germ cells.
a tumor arising from retinal cells.